CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2018 San Antonio Breast Cancer Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Spring on the Association Between pCR and Neoadjuvant Chemotherapy
Dr. Leon Ferre on the Results of the Randomized Trial of Oxybutynin for Hot Flashes
Dr. Bidard on the Clinical Utility of Circulating Tumor Cell Count in Breast Cancer
Oncology Conference Articles
TAILORx Update Shows Different PRO Profiles for Chemo, Endocrine Therapy for Breast Cancer
Chemotherapy for breast cancer caused significantly more acute symptoms as compared with endocrine therapy, although the adverse effects of endocrine therapy increased over time.
CAR T-Cell Therapy Shows Early Potential in TNBC
Chimeric antigen receptor T cells targeting the tyrosine kinase receptor ROR1 can be transferred into patients safely and the cells expand in vivo.
Telephone-Based Lifestyle Interventions Improved Breast Cancer Outcomes
Early-stage breast cancer survivors who completed a telephone-based lifestyle intervention program lost weight and tended to have higher rates of disease-free survival.
Durvalumab/Olaparib Combo Is Active in BRCA-Mutated Metastatic Breast Cancer
The combination of olaparib and durvalumab in patients with HER2-negative metastatic breast cancer with germline
mutations is well tolerated and has promising activity, especially in earlier settings.
Breast Cancer Surgery Choice May Affect Quality of Life in Younger Patients
Younger patients with breast cancer who underwent lumpectomy had better quality of life than women who had a mastectomy.
Exercise Helps Women Maintain Cardiovascular Function During Adjuvant Breast Cancer Treatment
Women who took part in a supervised exercise program during adjuvant treatment for breast cancer had better cardiovascular function than women who did not participate in the program.
Palbociclib Combo Active in HER2+ Breast Cancer
The combination of palbociclib and trastuzumab demonstrated safety and efficacy in patients with advanced estrogen receptor–positive/HER2-positive breast cancer.
Oxybutynin Decreases Hot Flashes, Improves Quality of Life in Breast Cancer Survivors
Oxybutynin helped to reduce the frequency and intensity of hot flashes among women who could not take hormone replacement therapy in survivorship.
Venetoclax Has Impressive Activity in ER+ and BCL-2+ Breast Cancer
Combining the BCL-2 inhibitor venetoclax with endocrine therapy elicited notable activity with a tolerable safety profile in patients with estrogen receptor–positive and BCL-2–positive metastatic breast cancer.
Extended PFS Observed in Alpelisib Combo for PIK3CA-Mutant Breast Cancer
Additional analyses from the SOLAR-1 study show that alpelisib, an investigational alpha-specific PI3K inhibitor, combined with fulvestrant extended progression-free survival compared with fulvestrant alone in patients with
-mutant advanced breast cancer regardless of line of therapy or prior CDK4/6 inhibitor treatment.
HER3-Targeting Antibody-Drug Conjugate Shows Encouraging Activity in Advanced Breast Cancer
U3-1402, an investigational antibody-drug conjugate targeting HER3, induced objective response in more than 40% of heavily pretreated patients with HER3-expressing breast cancer.
Axillary Radiotherapy Alternative to Lymph Node Dissection in Early-Stage Breast Cancer
Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy.
Accelerated PBI Not Equal to WBI in Ipsilateral Breast Tumor Recurrence
Accelerated partial breast irradiation following lumpectomy was marginally not found to be equivalent to whole breast irradiation to control ipsilateral breast tumor recurrence.
Myelopreservation Possible With CDK4/6 Inhibitor Trilaciclib in TNBC
A longer duration of chemotherapy exposure was possible in patients with metastatic triple-negative breast cancer who received trilaciclib, an investigational CDK4/6 inhibitor, in addition to gemcitabine and carboplatin (GC) compared with GC alone.
Lower-Dose Tamoxifen Reduces Recurrence Risk, Toxicity Incidence in Breast Cancer
The use of low-dose tamoxifen was shown to significantly reduce the risk of new and recurrent disease following surgery in women diagnosed with breast intraepithelial neoplasia but it did not cause more serious adverse events compared with placebo.
CTC Counts Demonstrate Selection Value in Metastatic Breast Cancer
The use of circulating tumor-cell counts demonstrated strong value for selecting endocrine therapy versus chemotherapy for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.
PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBC
Improvements observed in progression-free survival and overall survival with the addition of first-line atezolizumab to nab-paclitaxel in patients with metastatic triple negative breast cancer or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells.
Earlier Adjuvant Chemotherapy Benefits Patients With TNBC
Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure.
Association Between pCR and Neoadjuvant Chemo Shows Improved Breast Cancer Outcomes
Pathologic complete response following neoadjuvant chemotherapy appeared to be associated with improved survival outcomes among patients with breast cancer.
No Survival Benefit With Adjuvant Capecitabine in Early-Stage TNBC
Adjuvant treatment with capecitabine in patients with early-stage triple-negative breast cancer did not significantly improve disease-free or overall survival compared with observation, according to results from the phase III GEICAM/CIBOMA trial that were presented at the 2018 San Antonio Breast Cancer Symposium.
T-DM1 Likely New Adjuvant Standard in High-Risk HER2+ Breast Cancer
Ado-trastuzumab emtansine reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy.
OncLive News Network On Location: In San Diego Monday, December 3
Markman Outlines Biosimilars and Cost-Effective Oncology Practices
Landgren Explains Crucial Role of MRD in Myeloma
Enzalutamide/Radium-223 Combo Shows Potential in mCRPC
FDA Approves Romiplostim for Pediatric ITP
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.